Elicio Therapeutics, Inc. (ELTX) Operating income 2020–2025
Elicio Therapeutics, Inc. (ELTX) annual operating income history from SEC filings — each fiscal year as reported.
-$37.7MFY2025 · since FY2020: -$55.3M → -$37.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$37.7M | +16.2% |
| FY2024 | -$45.0M | -25.9% |
| FY2023 | -$35.7M | -50.6% |
| FY2022 | -$23.7M | +39.6% |
| FY2021 | -$39.3M | +28.9% |
| FY2020 | -$55.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTX financial trends
ELTX RevenueELTX Net incomeELTX Net marginELTX Gross profitELTX Gross marginELTX Operating marginELTX Operating cash flowELTX Free cash flowELTX Capital expendituresELTX Return on equityELTX Stock buybacksELTX Dividends paidELTX Total assetsELTX Total liabilitiesELTX Shareholders’ equityELTX overview →